# BLTE (Belite Bio, Inc.) - SEC EDGAR Financial Statements

> Belite Bio, Inc. reported $780.6M in total assets and a net loss of $77.61M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/BLTE
- Markdown: https://convexityos.com/fundamentals/BLTE.md
- SEC CIK: 0001889109
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:14 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001889109&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$84.21M | Operating profit |
| Net Income | FY 2025 | -$77.61M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.31 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$37.06M | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $352.9M | Total debt: $429K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $45.38M | $29.94M | $24.84M | $8.87M | $7.42M | $3.69M |
| Selling, General & Admin | $38.83M | $10.06M | $6.82M | -- | -- | -- |
| Total Operating Expenses | $84.21M | $40.00M | $31.67M | $12.82M | $9.80M | $5.74M |
| **Operating Income** | -$84.21M | -$40.00M | -$31.67M | -$12.82M | -$9.80M | -$5.74M |
| **EBITDA** | -$84.02M | -$39.83M | -$31.53M | -$12.76M | -$9.77M | -$5.73M |
| Interest Income | $6.64M | $3.74M | $74K | $23K | $5.0K | $12K |
| Interest Expense | $2.0K | $20K | $25K | $16K | -- | $21K |
| Income Before Tax | -$77.61M | -$36.14M | -$31.62M | -$12.65M | -$9.67M | -$5.75M |
| Income Tax Expense | $0 | $6.0K | $9.0K | -- | -- | $1.0K |
| **Net Income** | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| Basic EPS | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
| **Diluted EPS** | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
| Basic Shares Outstanding | 33.5M | 30.5M | 26.6M | 20.0M | 9.6M | 8.8M |
| Diluted Shares Outstanding | 33.5M | 30.5M | 26.6M | 20.0M | 9.6M | 8.8M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $352.9M | $31.68M | $88.16M | $42.09M | $17.34M |
| Short-Term Investments | -- | $4.55M | -- | -- | -- |
| **Cash & Short-Term Investments** | $352.9M | $36.23M | $88.16M | $42.09M | $17.34M |
| Other Current Assets | $5.0K | -- | -- | -- | -- |
| **Total Current Assets** | $494.3M | $147.1M | $89.94M | $42.81M | $17.43M |
| Property, Plant & Equipment, Net | $344K | $444K | $490K | $541K | $94K |
| Intangible Assets | $19K | $31K | -- | -- | -- |
| **Total Non-Current Assets** | $286.3M | $5.06M | $4.70M | $1.47M | $917K |
| **Total Assets** | $780.6M | $152.1M | $94.64M | $44.27M | $18.35M |
| Other Current Liabilities | $5.0K | $13K | -- | -- | -- |
| **Total Current Liabilities** | $9.88M | $6.05M | $3.63M | $2.10M | $1.64M |
| **Total Non-Current Liabilities** | $188K | $261K | $578K | $668K | $0 |
| **Total Liabilities** | $10.07M | $6.31M | $4.21M | $2.77M | $1.64M |
| **Total Debt (incl. Leases)** | $429K | $537K | $886K | $866K | -- |
| Common Stock | $4.0K | $3.0K | $3.0K | $3.0K | $1.0K |
| Retained Earnings | -$185.3M | -$107.6M | -$71.50M | -$39.87M | -$27.22M |
| Accumulated Other Comp. Income | -$536K | -$660K | -$374K | -$392K | -$196K |
| **Total Stockholders' Equity** | $770.5M | $145.8M | $90.43M | $41.50M | -$15.09M |
| Total Equity | $770.5M | $145.8M | $90.43M | $41.50M | -$15.09M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $352.9M | $31.68M | $88.16M | $42.09M | $17.34M |
| Short-Term Investments | -- | $4.55M | -- | -- | -- |
| **Cash & Short-Term Investments** | $352.9M | $36.23M | $88.16M | $42.09M | $17.34M |
| Other Current Assets | $5.0K | -- | -- | -- | -- |
| **Total Current Assets** | $494.3M | $147.1M | $89.94M | $42.81M | $17.43M |
| Property, Plant & Equipment, Net | $344K | $444K | $490K | $541K | $94K |
| Intangible Assets | $19K | $31K | -- | -- | -- |
| **Total Non-Current Assets** | $286.3M | $5.06M | $4.70M | $1.47M | $917K |
| **Total Assets** | $780.6M | $152.1M | $94.64M | $44.27M | $18.35M |
| Other Current Liabilities | $5.0K | $13K | -- | -- | -- |
| **Total Current Liabilities** | $9.88M | $6.05M | $3.63M | $2.10M | $1.64M |
| **Total Non-Current Liabilities** | $188K | $261K | $578K | $668K | $0 |
| **Total Liabilities** | $10.07M | $6.31M | $4.21M | $2.77M | $1.64M |
| **Total Debt (incl. Leases)** | $429K | $537K | $886K | $866K | -- |
| Common Stock | $4.0K | $3.0K | $3.0K | $3.0K | $1.0K |
| Retained Earnings | -$185.3M | -$107.6M | -$71.50M | -$39.87M | -$27.22M |
| Accumulated Other Comp. Income | -$536K | -$660K | -$374K | -$392K | -$196K |
| **Total Stockholders' Equity** | $770.5M | $145.8M | $90.43M | $41.50M | -$15.09M |
| Total Equity | $770.5M | $145.8M | $90.43M | $41.50M | -$15.09M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| Depreciation & Amortization | $184K | $168K | $139K | $64K | $30K | $17K |
| Stock-Based Compensation | $38.92M | $8.99M | $3.82M | $1.48M | $1.53M | $1.36M |
| **Operating Cash Flow** | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M | -$4.44M |
| Capital Expenditure | -$71K | -$116K | -$63K | -$394K | -$74K | -- |
| **Free Cash Flow** | -$37.06M | -$29.35M | -$29.90M | -$11.85M | -$7.55M | -- |
| Purchases of Investments | -- | -$4.50M | -- | -- | -- | -- |
| Sales & Maturities of Investments | -- | $77.84M | -- | -- | -- | -- |
| **Investing Cash Flow** | -$305.1M | -$110.6M | -$63K | -$394K | -$56K | -$20K |
| Common Stock Issued | -- | -- | -- | -- | -- | $500K |
| **Financing Cash Flow** | $663.2M | $83.59M | $75.96M | $36.96M | -$583K | $28.06M |
| **Net Change in Cash** | $321.3M | -$56.48M | $46.07M | $24.75M | -$8.27M | $23.60M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -10.1% | -24.8% | -35.0% | -30.5% | -- | -- |
| Return on Assets (ROA) | -9.9% | -23.8% | -33.4% | -28.6% | -52.7% | -- |
| Current Ratio | 50.02x | 24.31x | 24.76x | 20.35x | 10.66x | -- |
| Quick Ratio | 35.71x | 5.99x | 24.27x | 20.00x | 10.61x | -- |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.02x | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
